Summary
Check out our latest interview with SOPHiA GENETICS, a company revolutionizing healthcare by leveraging data-driven technology to improve the diagnosis and treatment of cancer and rare diseases. In this conversation with Paul Chilo, Director of Governance, Risk & Compliance, we explore UNITY, a global oncology platform, and discuss the compliance strategy behind this international initiative, as well as our collaboration in making it a reality.
Here is the latest interview with one of our clients - SOPHiA GENETICS,. SOPHiA GENETICS was founded in 2011 by biologists who saw an opportunity to address the growing need for answers to diseases of the DNA.
They believed technology could make a positive and lasting impact on the world, using data for good.Their vision was to build a future in which each patient has equal access to world-class care, and today, they are well underway to realizing that impact. SOPHia has built a technology platform that distills complex data into actionable insights to reshape the way that cancer and rare inherited disorders are diagnosed and treated.
In this interview with Paul Chilo, Director of Governance, Risk & Compliance at SOPHiA GENETICS, we explore the latest initiative, UNITY, a global oncology platform. We discuss SOPHiA GENETICS’ compliance strategy for this international project, as well as our collaboration and partnership in bringing it to life.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Navigating Privacy Requirements for Clinical Trials Across Jurisdictions: Focus on China
China’s data protection regulations play a crucial role in clinical trials, requiring sponsors and researchers to comply with multiple laws, including the PIPL, GCP-2020, and cross-border data transfer rules. Unlike other jurisdictions, China imposes strict consent requirements, risk assessments, and regulatory filings, making compliance a key factor when selecting trial locations and managing participant data.
